Post M J, Yiannoutsos C, Simpson D, Booss J, Clifford D B, Cohen B, McArthur J C, Hall C D
Department of Radiology, University of Miami School of Medicine, MRI Center, FL 33136, USA.
AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1896-906.
While MR findings in progressive multifocal leukoencephalopathy (PML) have been described previously, usually in retrospective studies with limited sample size, what has not been well addressed is whether any are predictive of longer survival. Our participation in a large prospective clinical trial of AIDS patients with biopsy-proved PML and MR correlation allowed us to test our hypothesis that certain MR features could be found favorable to patient survival.
The patient cohort derived from a randomized multicenter clinical trial of cytosine arabinoside for PML. Pretreatment T1- and T2-weighted noncontrast images (n = 48) and T1-weighted contrast-enhanced images (n = 45) of 48 HIV-positive patients with a PML tissue diagnosis as well as the follow-up images in 15 patients were reviewed to determine signal abnormalities, lesion location and size, and the presence or absence of mass effect, contrast enhancement, and atrophy, and to ascertain the frequency of these findings. A statistical analysis was performed to determine if any MR abnormalities, either at baseline or at follow-up, were predictive of patient survival.
No MR abnormalities either on univariate or multivariate analysis significantly correlated with patient survival, with the exception of mass effect, which was significantly associated with shorter survival. The mass effect, however, always minimal, was infrequent (five of 48). More severe degrees of cortical atrophy and ventricular dilatation, lesion location and size, and other MR variables were not predictive of outcome.
Except for mass effect, we found no MR findings predictive of the risk of death in patients with PML. The mass effect, however, was so infrequent and minimal that it was not a useful MR prognostic sign.
虽然先前已有关于进行性多灶性白质脑病(PML)磁共振成像(MR)表现的描述,通常是在样本量有限的回顾性研究中,但尚未充分探讨的是,是否有任何表现可预测更长的生存期。我们参与了一项针对经活检证实患有PML且有MR相关性的艾滋病患者的大型前瞻性临床试验,这使我们能够检验我们的假设,即某些MR特征可能对患者生存有利。
患者队列来自一项关于阿糖胞苷治疗PML的随机多中心临床试验。回顾了48例经PML组织诊断的HIV阳性患者的预处理T1加权和T2加权非增强图像(n = 48)以及T1加权增强图像(n = 45),以及15例患者的随访图像,以确定信号异常、病变位置和大小,以及是否存在占位效应、对比增强和萎缩,并确定这些表现的频率。进行了统计分析,以确定在基线或随访时的任何MR异常是否可预测患者生存。
单因素或多因素分析均未发现任何MR异常与患者生存显著相关,但占位效应除外,占位效应与较短生存期显著相关。然而,占位效应总是很轻微,很少见(48例中有5例)。更严重程度的皮质萎缩和脑室扩张、病变位置和大小以及其他MR变量均不能预测预后。
除占位效应外,我们未发现MR表现可预测PML患者的死亡风险。然而,占位效应非常少见且轻微,因此它不是一个有用的MR预后征象。